Cancers with an elevated mutational burden have been observed to demonstrate a greater likelihood of responding favorably to anti-CTLA-4 and anti-PD-1/PD-L1 therapies across a range of cancer types [10,242,243,244,245]. This evidence concerns the gene PDCD1 and cancer.